COMPOUND WITH CONFIDENCE: PCCA Membership, $795/month.

Pharmacy compounding's source for clinical information, regulatory updates, and opportunities

THE PCCA BLOG

rss

Stay current on PCCA news and events, market trends, and all things compounding!

_BB_DrugWipeSampling_800w.jpg

USP 800 discusses Environmental Quality and Control (Section 6) related to environmental wipe sampling for hazardous drug (HD) surface residue. This is not a requirement in USP 800; instead, it is stated that this should be performed routinely. What does this mean for those who handle HDs and why should compounders consider performing routine HD wipe sampling?

BB_ThinkNext-Recap_823x462.jpg

ThinkNext: International Seminar 2024 (ThinkNext: ISTX24), held October 17 - 19 in Houston, Texas, was a huge success with well over 500 rockstar compounders from around the world. We’re sharing seminar highlights and memorable takeaways that make PCCA members return year after year.

_BB_Hazardous Spills_800w.jpg

The United States Pharmacopeia (USP) General Chapter 800 addresses the handling of hazardous drugs (HDs) to minimize the risk of exposure to patients, health care workers and the environment. It became compendially applicable in November 2023. USP 800 contains some key elements that specifically apply to employee safety and HD containment. Section 16, for example, discusses managing HD spills and retaining spill kits on site. This article addresses HD spills that occur in a compounding pharmacy; however, it can be adapted for handling of non-HD chemical spills as well.

202405_BB_Quinacrine_900w.jpg

As one of the most studied synthetic drugs in modern history, quinacrine HCI was first used as an antimalarial and later to treat rheumatic skin diseases, including lupus. With May designated as Lupus Awareness month, learn more about quinacrine HCI and the twists and turns of its storied past.

202404_BB_ACT- Patients_900w.jpg

Compounding pharmacists are committed to helping their patients live healthier, better lives —and key to this is ensuring their patients have continuing access to lawfully prescribed, personalized medications tailored to their individual needs.

202403_BB_Best Practices_823x462.jpg

At PCCA, we proudly partner with our members to support the unique needs of your patients and prescribers through the science of compounding. We also recognize the importance of effectively communicating the value of compounded medications. As we navigate this path, it is crucial to adhere to established guidelines and embrace best practices in promoting your compounded medications.

20240105_BB-USP800_823x462.jpg

On November 1, 2023, revisions to USP Chapter 795 and Chapter 797 became official and made USP 800 compendially applicable and potentially enforceable. However, other regulatory agencies — including state boards of pharmacy and the FDA — may impact whether USP 800 is enforceable in your pharmacy.

202311_BB_ISTX23 Wrapup_823x46252.png

ThinkNext: International Seminar 2023 (ThinkNext: ISTX23) was a huge success, attended by more than 400 global participants. We’re reviewing the pearls — highlights of key takeaways — from the event to rekindle memories and, for those who missed attending, inspire your participation next year.

202310_Blog_Cleanroom2-Repost_1768x923.jpg

Due to pending USP updates that are effective on November 1, 2023, we’re reposting our January Blog, which reviews how a modular compounding cleanroom can meet evolving regulatory requirements and standards.

202309_BB_Oxytocin_823x462-B6.png

Review the criteria for selecting an FDA-approved API to safeguard your patients and your compounding pharmacy.